CustoMED has announced the successful completion of its seed round, bringing total funding to 6 million USD. The company will use the funding to scale its cloud-based platform, which combines artificial intelligence and automation with 3D printing to generate surgical tools and implants directly from a surgeon’s pre-operative plan.
The round includes investment from Longevity Venture Partners, Varana Capital, Flag Capital, the Israel Innovation Authority, a leading orthopaedic implant company, and Avishai Abrahami, Co-founder and CEO of Wix.
The patient-specific devices are produced onsite or through certified partners and integrate seamlessly into existing surgical workflows, enabling fewer intraoperative errors while allowing surgeons to maintain full creative and clinical control. The technology has already been used in hundreds of successful surgeries worldwide according to the company.
“CustoMED’s patient-specific surgical tools enable more precise orthopaedic surgeries through affordable, real-time solutions delivered directly into the operating room,” said Or Benifla, Co-founder of CustoMED. “By putting scalable, personalised technology directly in surgeons’ hands, our mission is to make computer-guided surgery fast, accessible, and routine, transforming what was once a boutique process into standard of care for every patient.”
CustoMED was founded by Dr. Amit Zabatani, Or Benifla, and Alon Jacobi, and originated from Sheba Medical Center’s 3D Printing & Innovation Lab, founded in 2018 by Dr. Dina Orkin together with the CustoMED co-founders.
The lab has supported hundreds of surgeries across multiple hospital departments, making 3D technologies a routine part of patient care. CustoMED is part of Sheba Medical Center’s ARC Innovation ecosystem, which fosters clinician-led innovations and accelerates global deployment.
“CustoMED is embedding precision and surgeon-directed tools into everyday workflows, shortening the path from imaging to the operating room while preserving governance, quality, and safety,” said Prof. Eyal Zimlichman, Founder and Director of ARC Innovation and Chief Innovation, Transformation, and AI Officer at Sheba Medical Center. “The company exemplifies ARC’s mission to translate clinical insight into scalable, real-world impact.”
Funding proceeds will accelerate CustoMED’s expansion into additional automated orthopedic indications, support U.S. and EU regulatory milestones, with approvals anticipated for 2026, and enable the global deployment of its on-demand manufacturing model.
“We were immediately impressed by the ARC team’s world-class experience and CustoMED’s mission to improve surgical performance and patient outcomes,” added Raissa Hacohen, Managing Partner at Longevity Venture Partners. “CustoMED’s platform gives surgeons everywhere access to personalised planning and surgical tools that can raise the standard of care in orthopedic surgery.”
